Spring til hovednavigation Spring til søgning Spring til hovedindhold

Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study

  • Qing Wang
  • , Andrea De Luca
  • , Colette Smith
  • , Robert Zangerle
  • , Helen Sambatakou
  • , Fabrice Bonnet
  • , Colette Smit
  • , Philipp Schommers
  • , Alicia Thornton
  • , Juan Berenguer
  • , Lars Peters
  • , Vincenzo Spagnuolo
  • , Adriana Ammassari
  • , Andrea Antinori
  • , Eugenia Quiros Roldan
  • , Cristina Mussini
  • , Jose M Miro
  • , Deborah Konopnicki
  • , Jan Fehr
  • , Maria A Campbell
  • Monique Termote, Hepatitis Coinfection and Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord
    51 Citationer (Scopus)

    Abstract

    Background: Non-Hodgkin lymphoma (NHL) is the most common AIDS-defining condition in the era of antiretroviral therapy (ART). Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection promote NHL in HIV-infected patients is unclear.

    Objective: To investigate whether chronic HBV and HCV infection are associated with increased incidence of NHL in HIV-infected patients.

    Design: Cohort study.

    Setting: 18 of 33 cohorts from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE).

    Patients: HIV-infected patients with information on HBV surface antigen measurements and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were not available.

    Measurements: Time-dependent Cox models to assess risk for NHL in treatment-naive patients and those initiating ART, with inverse probability weighting to control for informative censoring.

    Results: A total of 52 479 treatment-naive patients (1339 [2.6%] with chronic HBV infection and 7506 [14.3%] with HCV infection) were included, of whom 40 219 (77%) later started ART. The median follow-up was 13 months for treatment-naive patients and 50 months for those receiving ART. A total of 252 treatment-naive patients and 310 treated patients developed NHL, with incidence rates of 219 and 168 cases per 100 000 person-years, respectively. The hazard ratios for NHL with HBV and HCV infection were 1.33 (95% CI, 0.69 to 2.56) and 0.67 (CI, 0.40 to 1.12), respectively, in treatment-naive patients and 1.74 (CI, 1.08 to 2.82) and 1.73 (CI, 1.21 to 2.46), respectively, in treated patients.

    Limitation: Many treatment-naive patients later initiated ART, which limited the study of the associations of chronic HBV and HCV infection with NHL in this patient group.

    Conclusion: In HIV-infected patients receiving ART, chronic co-infection with HBV and HCV is associated with an increased risk for NHL.

    Primary Funding Source: European Union Seventh Framework Programme.

    OriginalsprogEngelsk
    TidsskriftAnnals of Internal Medicine
    Vol/bind166
    Udgave nummer1
    Sider (fra-til)9-17
    ISSN0003-4819
    DOI
    StatusUdgivet - 18 okt. 2017

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study'. Sammen danner de et unikt fingeraftryk.

    Citationsformater